Gilead Sciences Inc (NASDAQ:GILD) Director Richard James Whitley sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $78.63, for a total value of $393,150.00. Following the completion of the transaction, the director now directly owns 12,778 shares of the company’s stock, valued at approximately $1,004,734. Gilead Sciences, Inc. (NASDAQ:GILD)shares after opening at $76.73 moved to $ 79.91 on last trade day and at the end of the day closed at $79.83. Company price to sales ratio in past twelve months was calculated as 8.98and price to cash ratio as 17.90. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 7.76%.
Celgene Corporation (NASDAQ:CELG) Insider Perry A. Karsen sold 11,922 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $146.78, for a total value of $1,749,911.16. Following the transaction, the insider now directly owns 25,705 shares in the company, valued at approximately $3,772,980. Celgene Corporation (NASDAQ:CELG) shares advanced 0.65% in last trading session and ended the day on $148.36. CELG return on equity ratio is recorded as 24.00% and its return on assets is 10.70%. Celgene Corporation (NASDAQ:CELG) yearly performance is 21.97%.
Anika Therapeutics Inc (NASDAQ:ANIK) CEO Charles H. Sherwood sold 83,780 shares of the company’s stock on the open market in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $44.32, for a total transaction of $3,713,129.60. Anika Therapeutics, Inc. (NASDAQ:ANIK) shares moved up 4.84% in last trading session and was closed at $47.46 while trading in range of $4.30 – $47.78 – Anika Therapeutics, Inc. (NASDAQ:ANIK) year to date (YTD) performance is 24.37%.
Corcept Therapeutics (NASDAQ:CORT) Director Longitude Venture Partners L.P sold 250,000 shares of the company’s stock on the open market in a transaction dated Friday, May 2nd. The stock was sold at an average price of $4.11, for a total value of $1,027,500.00.Corcept Therapeutics Incorporated (NASDAQ:CORT) weekly performance is 6.35%. On last trading day company shares ended up $4.15. Corcept Therapeutics Incorporated (NASDAQ:CORT) distance from 50-day simple moving average (SMA50) is 5.33%. Analysts mean target price for the company is $3.50.